Navigation Links
CT angiography may be unnecessary in patients with suspected pulmonary embolism

OAK BROOK, Ill. A new study suggests that computed tomography (CT) angiography might be unnecessary in many patients suspected of having pulmonary embolism (PE), based on the results of risk assessment analysis. PE risk assessment could help reduce radiation exposure and costs associated with CT angiography. The results of the study appear in the online edition and August print issue of the journal Radiology.

"Our study suggests that the frequency of ordering CT angiograms can be markedly reduced with resultant cost-savings and decreased radiation exposure," said lead author Mark D. Mamlouk, M.D., radiology resident at the University of California, Irvine in Orange, Calif.

Pulmonary embolism occurs when a blood clot, usually from the leg, travels through the bloodstream and gets lodged in a pulmonary artery. The condition can be fatal, so prompt diagnosis is critical.

CT angiography's high sensitivity and specificity has made it the preferred modality for diagnosing PE. However, the increasing use of the examination has fueled concerns over procedure costs and radiation exposure to patients, along with risks associated with the use of contrast agents.

For the study, the researchers assessed the possibility of using risk factors associated with thromboembolism, or blood clot formation, to reduce the number of CT angiograms for PE. They reviewed the electronic medical records of 2,003 patients who underwent CT angiography for possible PE between July 2004 and February 2006. Among the risk factors assessed were age, history of immobilization and cancer. Other risk factors included excess estrogen state, a history of venous thromboembolism, gender and disorders that cause blood to clot more easily than normal.

Overall, CT angiograms were negative for PE in 1,806 of 2,003 patients, or 90.2 percent. Among the 197 patients with CT angiograms positive for PE, 192, or 97.5 percent, had one or more risk factors.

All of the risk factors except gender were determined to be statistically significant. Age of 65 years or older and immobilization were the most common risk factors in positive PE patients.

Of the 1,806 patients with CT angiograms negative for PE, 520 (28.8 percent) had no risk factors. Furthermore, excluding age and gender, 1,119 (62 percent) had no risk factors. Risk factor assessment had a sensitivity of 97.5 percent and a negative predictive value of 99 percent in all patients.

Without any thromboembolic risk factors, there was only a 0.95 percent chance of a CT angiogram positive for PE, according to Dr. Mamlouk.

"Thromboembolic risk factor assessment is an effective clinical method to determine when to perform CT angiography for PE," Dr. Mamlouk said. "Risk assessment can be performed when clinicians acquire their patients' history. It takes only a few minutes, and there's no cost."

Dr. Mamlouk and colleagues also concluded that the combination of no risk factors and a negative D-dimer, a blood test that helps in the diagnosis of blood clots, yielded an extraordinarily low risk for a positive CT angiogram for PE.


Contact: Linda Brooks
Radiological Society of North America

Related medicine news :

1. Carotid artery ultrasound is an effective alternative to more invasive coronary angiography
2. CT Scan Patients May Get Unnecessary Imaging
3. Unindicated CT series result in unnecessary radiation exposure for patients
4. Elastography reduces unnecessary breast biopsies
5. Sandwich Generation Avoids Unnecessary Stress While Tending to Aging Senior Parents
6. Imaging manufacturers: Plan to reduce unnecessary radiation exposure and medical errors
7. Poll: One of Four Healthcare Dollars Spent on Unnecessary Medical Care
8. Avoiding Dairy Due to Lactose Intolerance is Unnecessary in Most Cases and May Pose Diet and Health Risks, Concludes National Institutes of Health Consensus Development Conference Panel
9. Simple change results in fewer unnecessary imaging exams for patients
10. Matching Heart Donors by Race Unnecessary?
11. Targeted therapy prolongs life in patients with HER2-positive breast cancer
Post Your Comments:
(Date:11/26/2015)... TX (PRWEB) , ... November 26, 2015 , ... PRMA ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! ... “We wake up every day excited to rebuild lives and it’s an honor to ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film ... trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 ... with any font, giving users limitless opportunities to stylize and create designs quickly ...
(Date:11/26/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact center software Q-Suite, ... The new Q-Suite 6 platform is based on the latest Java Enterprise standards. By ... piece of software for many key components of the suite. Much of the suite ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... ... 2015 , ... Finnleo, a leader in the traditional and far-infrared sauna industry, ... far-infrared saunas. , For traditional saunas, Finnleo is offering 20% off ... and Finnleo uses only European Grade A Nordic White Spruce from sustainably grown trees. ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology: